Phenotypes associated with this allele

• Allele Symbol: Egfr^wa2
• Allele Name: waved 2
• Allele ID: MGI:1856397
• Summary: 21 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Egfr^wa2/Egfr^wa2	B6EiC3Sn a/A-Egfr^wa2 Wnt3a^vt/J	MGI:2176536
hm2	Egfr^wa2/Egfr^wa2	involves: C57BL/6	MGI:5905421
hm3	Egfr^wa2/Egfr^wa2	STOCK ac	MGI:2176535
hm4	Egfr^wa2/Egfr^wa2	STOCK Egfr^wa2	MGI:2176568
ht5	Egfr^tm1Mag/Egfr^wa2	involves: 129S2/SvPas * B6EiC3Sn a/A-Egfr^wa2 Wnt3a^vt * CD-1	MGI:2176562
ht6	Egfr^wa2/Egfr^Wa5	involves: BALB/cAnN * C3H/HeN * C57BL/6J	MGI:3623313
cn7	Chuk^tm1Yhu/Chuk^tm1Yhu Egfr^wa2/Egfr^wa2 Tg(KRT5-cre)5132Jlj/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3817621
cx8	Egfr^wa2/Egfr^wa2 Ptpn11^tm1Rbn/Ptpn11^+	involves: 129 * B6EiC3Sn-a/A-Egfr^wa2 Wnt3a^vt	MGI:2176546
cx9	Egfr^wa2/Egfr^wa2 Errfi1^tm1Kln/Errfi1^tm1Kln	involves: 129P2/OlaHsd * C3H/HeSnJ * C57BL/6	MGI:3639758
cx10	Egfr^wa2/Egfr^+ Errfi1^tm1Kln/Errfi1^tm1Kln	involves: 129P2/OlaHsd * C3H/HeSnJ * C57BL/6	MGI:3639757
cx11	Egfr^wa2/Egfr^+ Fos^tm2(Fosl1)Wag/Fos^tm2(Fosl1)Wag Tg(KRT5-SOS1)892A6Wag/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:5142271
cx12	Egfr^wa2/Egfr^+ Fos^tm4.1Wag/Fos^tm4.1Wag Tg(KRT5-SOS1)892A6Wag/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:5142272
cx13	Egfr^wa2/Egfr^+ Fos^tm3.1Wag/Fos^tm3.1Wag Tg(KRT5-SOS1)892A6Wag/0	involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL	MGI:5142269
cx14	Egfr^wa2/Egfr^+ Fos^tm5.1Wag/Fos^tm5.1Wag Tg(KRT5-SOS1)892A6Wag/0	involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL	MGI:5142267
cx15	Egfr^wa2/Egfr^+ Fos^tm6.1Wag/Fos^tm6.1Wag Tg(KRT5-SOS1)892A6Wag/0	involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL	MGI:5142268
cx16	Egfr^wa2/Egfr^wa2 Sos1^tm1Dlb/Sos1^+	involves: 129S1/Sv * 129X1/SvJ * B6EiC3Sn-a/A-Egfr^wa2 Wnt3a^vt	MGI:2176918
cx17	Egfr^wa2/Egfr^wa2 Ptpn11^tm1Paw/Ptpn11^+	involves: 129S1/Sv * 129X1/SvJ * B6EiC3Sn a/A-Egfr^wa2 Wnt3a^vt * C57BL/6	MGI:2176569
cx18	Egfr^wa2/Egfr^wa2 Ereg^tm1Dwt/Ereg^tm1Dwt	involves: 129S6/SvEvTac	MGI:3512136
cx19	Egfr^wa2/Egfr^+ Nf1^tm1Fcr/Nf1^+ Trp53^tm1Brd/Trp53^+	involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6 * C57BL/6JEi * C3H/HeSnJ	MGI:5485354
cx20	Egfr^wa2/Egfr^+ Rps6ka3^tm1.1Kry/Y Tg(KRT5-SOS1)892A6Wag/0	involves: 129X1/SvJ * C57BL/6 * CBA	MGI:5142270
cx21	Egfr^wa2/Egfr^+ Tg(KRT5-SOS1)892A6Wag/0	involves: C57BL/6 * CBA	MGI:5142266

Genotype
MGI:2176536

hm1

• Allelic Composition: Egfr^wa2/Egfr^wa2
• Genetic Background: B6EiC3Sn a/A-Egfr^wa2 Wnt3a^vt/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Mammary gland histology of an Egfr^wa2/Egfr^wa2 mouse

cardiovascular system

enlarged aortic valve ( J:60750 )

• enlarged/thickened aortic valves

thick aortic valve ( J:60750 )

endocrine/exocrine glands

abnormal mammary gland morphology ( J:23326 )

♀ • small mammary glands and the ratio of gland to adipose tissue is reduced

abnormal lactation ( J:23326 )

♀ • reduction of milk within ducts of mammary glands and secretory vacuolation within lobules is less pronounced

integument

abnormal mammary gland morphology ( J:23326 )

♀ • small mammary glands and the ratio of gland to adipose tissue is reduced

abnormal lactation ( J:23326 )

♀ • reduction of milk within ducts of mammary glands and secretory vacuolation within lobules is less pronounced

abnormal hair texture ( J:16986 )

abnormal vibrissa morphology ( J:16986 )

Genotype
MGI:5905421

hm2

• Allelic Composition: Egfr^wa2/Egfr^wa2
• Genetic Background: involves: C57BL/6

cardiovascular system

abnormal aorta morphology ( J:241813 )

• aortic enlargement at 1.5 months of age

• aortic diameters at the level of the sinuses of Valsalva and at the level of the proximal ascending aorta are increased at all ages

abnormal myocardial fiber morphology ( J:241813 )

• myocardial transverse tubule organization is disrupted at 12 months of age but not at 1.5 and 3 months

abnormal heart left ventricle morphology ( J:241813 )

• left ventricle mass, indexed to body mass, is elevated at 1.5, 6, and 12 months of age

• pioglitazone treatment has no effect on left ventricle mass

abnormal aortic valve morphology ( J:241813 )

• aortic valve collagen levels are normal at 1.5 months of age but are increased at 6 and 12 months of age

• lipid levels are increased in aortic valves at 6 and 12 months of age but not at 1.5 months

• levels of proteoglycan in the aortic valve are elevated at 1.5, 6, and 12 months of age

• alpha-smooth muscle actin levels are elevated in aortic valves at 6 and 12 months of age but not at 1.5 months, indicating transdifferentiation of valve interstitial cells from a quiescent state to a profibrotic state

• intact versican is increased while cleaved versican is reduced in aortic valves at 6 months of age indicating increased levels of total proteoglycan

• however, levels of biglycan are normal

• pioglitazone treatment has no effect on collagen levels, on aortic valve lipid levels, on aortic valve alpha-smooth muscle actin levels, or on intact or cleaved versican levels

aortic valve stenosis ( J:241813 )

• 3 of 55 mice show an aortic cup separation of <0.66 mm, indicating a low level of aortic stenosis

• aortic cusp separation is normal in most mice and aortic cusp movement is symmetrical at all ages

calcified aortic valve ( J:241813 )

• aortic valve calcification is increased at 6 and 12 months of age but not at 1.5 months

• marker analysis indicates osteogenic transformation in the aortic valve at 6 and 12 months of age but not at 1.5 months

• pioglitazone treatment reduces valve calcification

increased heart left ventricle size ( J:241813 )

• left ventricle chamber enlargement at 1.5, 6, and 12 months of age

heart left ventricle hypertrophy ( J:241813 )

• left ventricle hypertrophy at 1.5 and 3 months of age, at a time when left ventricle systolic function is normal

cardiac fibrosis ( J:241813 )

• fibrosis is evident in the myocardium at 12 months of age

increased cardiac stroke volume ( J:241813 )

• left ventricle stroke volume is increased at 1.5, 6, and 12 months of age

• however, stroke volume is not increased in the 30% of mice that do not have aortic regurgitation at 1.5 months of age

• pioglitazone treatment has no effect on left ventricle stroke volume

decreased heart ventricle muscle contractility ( J:241813 )

decreased heart left ventricle muscle contractility ( J:241813 )

• left ventricle ejection fraction is decreased by 12 months of age but not at 1.5 and 6 months of age

• by 12 months of age, a trend toward greater left ventricular dilation and lower left ventricle ejection fraction in females than in males

decreased heart right ventricle muscle contractility ( J:241813 )

• right ventricle ejection fraction is decreased at 6 months of age

abnormal heart valve physiology ( J:241813 )

• an increase in apoptosis in the aortic valve is seen at 6 and 12 months of age, but not at 1.5 months

• elevation of transvalvular gradients in aortic valves

• treatment with pioglitazone prevents increases in apoptosis

aortic valve regurgitation ( J:241813 )

• prevalence of moderate or severe aortic regurgitation is 70%, 81%, and 73% at 1.5, 6, and 12 months of age, respectively

• all mice with aortic stenosis also have severe aortic regurgitation with diastolic prolapse of more than or equal to 1 valve cusps into the left ventricular outflow tract

• however, mitral regurgitation is absent

• pioglitazone treatment has no effect on prevalence of aortic regurgitation

increased pulse pressure ( J:241813 )

• increase in transvalvular gradients associated with increased aortic pulse pressure

muscle

abnormal myocardial fiber morphology ( J:241813 )

• myocardial transverse tubule organization is disrupted at 12 months of age but not at 1.5 and 3 months

heart left ventricle hypertrophy ( J:241813 )

• left ventricle hypertrophy at 1.5 and 3 months of age, at a time when left ventricle systolic function is normal

decreased heart ventricle muscle contractility ( J:241813 )

decreased heart left ventricle muscle contractility ( J:241813 )

• left ventricle ejection fraction is decreased by 12 months of age but not at 1.5 and 6 months of age

• by 12 months of age, a trend toward greater left ventricular dilation and lower left ventricle ejection fraction in females than in males

decreased heart right ventricle muscle contractility ( J:241813 )

• right ventricle ejection fraction is decreased at 6 months of age

growth/size/body

heart left ventricle hypertrophy ( J:241813 )

• left ventricle hypertrophy at 1.5 and 3 months of age, at a time when left ventricle systolic function is normal

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
aortic valve disease		DOID:62		J:241813

Genotype
MGI:2176535

hm3

• Allelic Composition: Egfr^wa2/Egfr^wa2
• Genetic Background: STOCK ac

growth/size/body

decreased body size ( J:13052 )

integument

short hair ( J:13052 )

• coat length remains shorter

waved hair ( J:5260 , J:13052 )

• aggregation chimeras between Egfr^wa2/Egfr^wa2 and +/+ embryos result in a patchy distribution of waved and normal hair, suggesting that Egfr^wa2 acts locally in the hair follicle cells (J:5260)

• waviness of hair appears as soon as the coat develops, at 7-8 days of age (J:13052)

• coat waviness increases from 4th to 6th weeks of age but decreases during 7-8 weeks of age (J:13052)

• waviness may disappear entirely or may be evident to a slight degree throughout life (J:13052)

abnormal hair cortex keratinization ( J:5260 )

• cortex of hair shaft is thickened

abnormal hair medulla ( J:5260 )

• hairs have irregularities and narrowing of the medulla

increased curvature of hairs ( J:5260 )

• occurs where the medulla is irregular and narrowed

increased curvature of guard hairs ( J:13052 )

• when coat is most waved, the guard hairs are frizzled

• guard hairs remain curved even though coat waviness decreases over time

curly vibrissae ( J:13052 )

• vibrissae are bent upon the second day and are distinctly curled by 4-5 days of age

• vibrissae remain curled event though coat waviness decreases or disappears

short vibrissae ( J:13052 )

vision/eye

abnormal eye morphology ( J:15329 )

• Background Sensitivity: a squint and/or cataract phenotype occurs in this genotype with penetrance of 81 percent

cataract ( J:15329 )

Genotype
MGI:2176568

hm4

• Allelic Composition: Egfr^wa2/Egfr^wa2
• Genetic Background: STOCK Egfr^wa2

cardiovascular system

abnormal aortic valve morphology ( J:60750 )

• aortic valve size ranges from unaffected to mildly or markedly thickened

enlarged semilunar valve ( J:60750 )

• about 80% exhibit semilunar valve enlargement

aortic valve regurgitation ( J:60750 )

• valve abnormalities persist into adulthood causing moderate to severe regurgitation

increased left ventricle systolic pressure ( J:60750 )

• higher peak left ventricular systolic pressure and a trend towards increased +dP/dT

prolonged RR interval ( J:60750 )

prolonged PR interval ( J:60750 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
aortic valve disease		DOID:62		J:60750

Genotype
MGI:2176562

ht5

• Allelic Composition: Egfr^tm1Mag/Egfr^wa2
• Genetic Background: involves: 129S2/SvPas * B6EiC3Sn a/A-Egfr^wa2 Wnt3a^vt * CD-1

cardiovascular system

thick aortic valve ( J:60750 )

• thickened aortic valves

Genotype
MGI:3623313

ht6

• Allelic Composition: Egfr^wa2/Egfr^Wa5
• Genetic Background: involves: BALB/cAnN * C3H/HeN * C57BL/6J

Phenotypes of Egfr^wa2/Egfr^Wa5 and Tgfa^tm1Unc/Tgfa^tm1Unc Egfr^Wa5/⁺ mice

mortality/aging

perinatal lethality, incomplete penetrance ( J:92308 )

• born at about half the expected rate

postnatal lethality, incomplete penetrance ( J:92308 )

• heavy death rate over the first 3 weeks of life

growth/size/body

asymmetric snout ( J:92308 )

• narrow, asymmetric snout

long snout ( J:92308 )

• elongated snout

narrow snout ( J:92308 )

• narrow, asymmetric snout

decreased body weight ( J:92308 )

• body weight ranges from 30-50% of controls in mutants that survive for 3 months after birth

postnatal growth retardation ( J:92308 )

• 25% reduction in body size in mice surviving to 6 weeks of age

craniofacial

mandible hypoplasia ( J:92308 )

• underdeveloped lower jaw

asymmetric snout ( J:92308 )

• narrow, asymmetric snout

long snout ( J:92308 )

• elongated snout

narrow snout ( J:92308 )

• narrow, asymmetric snout

reproductive system

abnormal vagina orifice morphology ( J:92308 )

♀ • vaginal opening delayed until around 11 months of age

abnormal fertility/fecundity ( J:92308 )

• no offspring produced by either gender by 3 months of age

skeleton

mandible hypoplasia ( J:92308 )

• underdeveloped lower jaw

vision/eye

abnormal eye morphology ( J:92308 )

• eye defects

integument

alopecia ( J:92308 )

• complete hair loss occurs around 8 weeks of age with resumption of hair growth sometime thereafter

loss of vibrissae ( J:92308 )

Genotype
MGI:3817621

cn7

• Allelic Composition: Chuk^tm1Yhu/Chuk^tm1Yhu; Egfr^wa2/Egfr^wa2; Tg(KRT5-cre)5132Jlj/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

premature death ( J:141162 )

integument

integument phenotype ( J:141162 )

N • mice exhibit normal epidermal thickness

abnormal epidermal layer morphology ( J:141162 )

• epidermal proliferation is less than in Chuk^tm1Yhu/Chuk^tm1Yhu Tg(KRT5-cre)1Jlj mice

Genotype
MGI:2176546

cx8

• Allelic Composition: Egfr^wa2/Egfr^wa2; Ptpn11^tm1Rbn/Ptpn11⁺
• Genetic Background: involves: 129 * B6EiC3Sn-a/A-Egfr^wa2 Wnt3a^vt

muscle

myocardium hypertrophy ( J:60750 )

• develop myocardial hypertrophy

mortality/aging

perinatal lethality, incomplete penetrance ( J:60750 )

• fewer mutants than predicted are seen at P10, however observe no deaths between P1 and P10, indicating embryonic lethality or death soon after birth

cardiovascular system

myocardium hypertrophy ( J:60750 )

• develop myocardial hypertrophy

aortic valve stenosis ( J:60750 )

• valve abnormalities persist into adulthood causing mild to moderate aortic stenosis

thick aortic valve ( J:60750 )

• aortic valve is thickened

thick pulmonary valve ( J:60750 )

• pulmonary valve is thickened

enlarged semilunar valve ( J:60750 )

• exhibit semilunar valve enlargement resulting from over-abundant mesenchymal cells

• however, atrioventricular valves and interventricular septum are unaffected

aortic valve regurgitation ( J:60750 )

• valve abnormalities persist into adulthood causing moderate to severe regurgitation

increased left ventricle diastolic pressure ( J:60750 )

• elevation in left-ventricular-end-diastolic pressures, reflecting diastolic dysfunction and possibly incipient heart failure

increased left ventricle systolic pressure ( J:60750 )

• higher peak left ventricular systolic pressure and a trend towards increased +dP/dT

abnormal impulse conducting system conduction ( J:60750 )

• severe conduction system abnormalities

prolonged RR interval ( J:60750 )

prolonged PR interval ( J:60750 )

prolonged QRS complex duration ( J:60750 )

• slightly prolonged QRS

prolonged QT interval ( J:60750 )

prolonged ST segment ( J:60750 )

• prolonged ST interval

increased systemic arterial blood pressure ( J:60750 )

congestive heart failure ( J:60750 )

• occasionally show cardiac dilation characteristic of congestive heart failure

vision/eye

eyelids open at birth ( J:60750 )

• display defective eyelid closure

growth/size/body

myocardium hypertrophy ( J:60750 )

• develop myocardial hypertrophy

Genotype
MGI:3639758

cx9

• Allelic Composition: Egfr^wa2/Egfr^wa2; Errfi1^tm1Kln/Errfi1^tm1Kln
• Genetic Background: involves: 129P2/OlaHsd * C3H/HeSnJ * C57BL/6

integument

integument phenotype ( J:109556 )

N • skin phenotype seen in Egfrwa2/+, Errfi1^tm1Kln homozygotes and single Errfi1^tm1Kln homozygotes is completely rescued in double knockouts

Genotype
MGI:3639757

cx10

• Allelic Composition: Egfr^wa2/Egfr⁺; Errfi1^tm1Kln/Errfi1^tm1Kln
• Genetic Background: involves: 129P2/OlaHsd * C3H/HeSnJ * C57BL/6

integument

abnormal skin morphology ( J:109556 )

• mice display similar epidermal thickening, suprabasal proliferation and impaired differentiation as Errfi1^tm1Kln homozygotes

Genotype
MGI:5142271

cx11

• Allelic Composition: Egfr^wa2/Egfr⁺; Fos^{tm2(Fosl1)Wag}/Fos^{tm2(Fosl1)Wag}; Tg(KRT5-SOS1)892A6Wag/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

neoplasm

increased skin papilloma incidence ( J:175064 )

decreased tumor growth/size ( J:175064 )

• tumor burden is reduced compared to in Tg(KRT5-SOS1)892A6Mka mice

integument

increased skin papilloma incidence ( J:175064 )

Genotype
MGI:5142272

cx12

• Allelic Composition: Egfr^wa2/Egfr⁺; Fos^tm4.1Wag/Fos^tm4.1Wag; Tg(KRT5-SOS1)892A6Wag/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

neoplasm

increased skin papilloma incidence ( J:175064 )

• mice exhibit the same tumor burden as Tg(KRT5-SOS1)892A6Mka mice

integument

increased skin papilloma incidence ( J:175064 )

• mice exhibit the same tumor burden as Tg(KRT5-SOS1)892A6Mka mice

Genotype
MGI:5142269

cx13

• Allelic Composition: Egfr^wa2/Egfr⁺; Fos^tm3.1Wag/Fos^tm3.1Wag; Tg(KRT5-SOS1)892A6Wag/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL

neoplasm

increased skin papilloma incidence ( J:175064 )

decreased tumor growth/size ( J:175064 )

• tumor burden is reduced compared to in Tg(KRT5-SOS1)892A6Mka mice

integument

increased skin papilloma incidence ( J:175064 )

Genotype
MGI:5142267

cx14

• Allelic Composition: Egfr^wa2/Egfr⁺; Fos^tm5.1Wag/Fos^tm5.1Wag; Tg(KRT5-SOS1)892A6Wag/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL

neoplasm

increased skin tumor incidence ( J:175064 )

increased skin papilloma incidence ( J:175064 )

decreased tumor growth/size ( J:175064 )

• at 4 weeks, tumor volume is decreased 50% compared to in Tg(KRT5-SOS1)892A6Mka mice

integument

increased skin tumor incidence ( J:175064 )

increased skin papilloma incidence ( J:175064 )

Genotype
MGI:5142268

cx15

• Allelic Composition: Egfr^wa2/Egfr⁺; Fos^tm6.1Wag/Fos^tm6.1Wag; Tg(KRT5-SOS1)892A6Wag/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL

neoplasm

increased skin papilloma incidence ( J:175064 )

• papillomas are larger than in Tg(KRT5-SOS1)892A6Mka mice

increased tumor growth/size ( J:175064 )

integument

increased skin papilloma incidence ( J:175064 )

• papillomas are larger than in Tg(KRT5-SOS1)892A6Mka mice

Genotype
MGI:2176918

cx16

• Allelic Composition: Egfr^wa2/Egfr^wa2; Sos1^tm1Dlb/Sos1⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * B6EiC3Sn-a/A-Egfr^wa2 Wnt3a^vt

mortality/aging

preweaning lethality, incomplete penetrance ( J:38321 )

• lower than expected numbers of pups are obtained at weaning, although some survive to adulthood

cardiovascular system

cornea vascularization ( J:38321 )

vision/eye

abnormal ciliary body morphology ( J:38321 )

• ciliary body is either absent or rudimentary

abnormal cornea morphology ( J:38321 )

• cornea is thickened and shows signs of neovascularization, and contains fragments of pigmented tissue

cornea vascularization ( J:38321 )

anterior iris synechia ( J:38321 )

• lens and iris are attached to the cornea

increased cornea thickness ( J:38321 )

cornea opacity ( J:38321 )

• 1/3 develop a unilateral corneal opacity either at weaning or by 4 months of age

fused cornea and lens ( J:38321 )

• lens and iris are attached to the cornea

abnormal eye anterior chamber morphology ( J:38321 )

• anterior chamber is hypotrophic

lens vacuoles ( J:38321 )

abnormal lens fiber morphology ( J:38321 )

• lens has disorganized fibers

small lens ( J:38321 )

• lens in some mice is reduced in size

microphthalmia ( J:38321 )

• 1/3 develop unilateral microphthalmia either at weaning or by 4 months of age

eyelids open at birth ( J:38321 )

abnormal retina morphology ( J:38321 )

• retina exhibits areas of focal disorganization

Genotype
MGI:2176569

cx17

• Allelic Composition: Egfr^wa2/Egfr^wa2; Ptpn11^tm1Paw/Ptpn11⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * B6EiC3Sn a/A-Egfr^wa2 Wnt3a^vt * C57BL/6

Defects in the skin, lung and intestine of Egfr^wa2/Egfr^wa2 Ptpn11^tm1Paw/⁺ mice

mortality/aging

postnatal lethality, incomplete penetrance ( J:75413 )

• only 30% survive to weaning, with most dying within 7-10 days after birth

growth/size/body

cachexia ( J:75413 )

• exhibit progressive wasting

postnatal growth retardation ( J:75413 )

muscle

intestinal hypoperistalsis ( J:75413 )

• lumen of stomach and small and large bowels are filled with desquamated epithelial cells, suggesting lack of peristalsis

abnormal muscle morphology ( J:75413 )

• decrease in the size of subcutaneous muscle tissue

respiratory system

abnormal lung development ( J:75413 )

• lungs are immaturely developed with poorly inflated areas

atelectasis ( J:75413 )

thick pulmonary interalveolar septum ( J:75413 )

• increase in thickness and cell masses of the alveolar septae

abnormal breathing pattern ( J:75413 )

• display breathing difficulties

vision/eye

eyelids open at birth ( J:75413 )

adipose tissue

decreased subcutaneous adipose tissue amount ( J:75413 )

• decrease in the size of subcutaneous fat tissue

digestive/alimentary system

abnormal intestine morphology ( J:75413 )

• the muscle layer of the bowel is poorly organized and is decreased in thickness

intestinal hypoperistalsis ( J:75413 )

• lumen of stomach and small and large bowels are filled with desquamated epithelial cells, suggesting lack of peristalsis

integument

decreased subcutaneous adipose tissue amount ( J:75413 )

• decrease in the size of subcutaneous fat tissue

abnormal hair growth ( J:75413 )

• little hair outgrowth

waved hair ( J:75413 )

abnormal hair follicle morphology ( J:75413 )

abnormal hair follicle development ( J:75413 )

• poorly developed hair follicles

abnormal hair follicle orientation ( J:75413 )

• hair follicles are disordered

decreased hair follicle number ( J:75413 )

• skin contains no or few disorganized hair follicles

epidermal atrophy ( J:75413 )

• hypotrophy in the epidermis

thin epidermis ( J:75413 )

dry skin ( J:75413 )

• skin gradually becomes dry and flaky

flaky skin ( J:75413 )

• skin gradually becomes dry and flaky

abnormal skin condition ( J:75413 )

thin skin ( J:75413 )

Genotype
MGI:3512136

cx18

• Allelic Composition: Egfr^wa2/Egfr^wa2; Ereg^tm1Dwt/Ereg^tm1Dwt
• Genetic Background: involves: 129S6/SvEvTac

normal phenotype

no abnormal phenotype detected ( J:93327 )

• no gross abnormalities were detected and liver regeneration following partial hepatectomy was normal

Genotype
MGI:5485354

cx19

• Allelic Composition: Egfr^wa2/Egfr⁺; Nf1^tm1Fcr/Nf1⁺; Trp53^tm1Brd/Trp53⁺
• Genetic Background: involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6 * C57BL/6JEi * C3H/HeSnJ

neoplasm

decreased tumor incidence ( J:95933 )

• only 1 of 17 (5.9%) mice develop a tumor, a spindle cell tumor compared to 57.9% of double heterozygous Nf1 and Trp53 mutants; this mouse was sacrificed at 21 weeks of age

Genotype
MGI:5142270

cx20

• Allelic Composition: Egfr^wa2/Egfr⁺; Rps6ka3^tm1.1Kry/Y; Tg(KRT5-SOS1)892A6Wag/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * CBA

neoplasm

increased skin papilloma incidence ( J:175064 )

♂

decreased tumor growth/size ( J:175064 )

♂ • tumor burden is reduced compared to in Tg(KRT5-SOS1)892A6Mka mice

integument

increased skin papilloma incidence ( J:175064 )

♂

Genotype
MGI:5142266

cx21

• Allelic Composition: Egfr^wa2/Egfr⁺; Tg(KRT5-SOS1)892A6Wag/0
• Genetic Background: involves: C57BL/6 * CBA

integument

increased skin tumor incidence ( J:175064 )

increased skin papilloma incidence ( J:175064 )

neoplasm

increased skin tumor incidence ( J:175064 )

increased skin papilloma incidence ( J:175064 )